1. Generics Bulletin
  2. >>Products

Teva Puts End Of 2022 Ambition On Nationwide US Opioids Settlement

‘We Believe We’re Getting Closer,’ Says CEO Kåre Schultz

 
• By Dean Rudge

After adding more than $1bn to its legal settlement contingency in Q1, Teva has given its clearest indication yet for when it expects to announce a nationwide deal in the US to settle opioid-related claims. The Israeli firm is facing two bench trials in the coming weeks and months but is optimistic on that front also.

Flags
Teva has nationwide ambitions with a trial in California to come • Source: Shutterstock: Savvapanf Photo

Buoyed by recent state-level opioid settlements, Teva’s president and CEO Kåre Schultz is “slightly more optimistic on the time schedule now” for a potential deal spanning the whole of the US. “I hope that we will see a nationwide settlement before the end of this year,” Schultz has declared.

The Israeli giant had at the end of March brokered its second individual state opioid settlement in as many weeks, having reached an agreement with the attorney general of Florida

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Generics

More from Products

Micro Labs Agrees To 15-Year Freeze On US Bempedoic Acid Rival

 
• By Dean Rudge

Eight more ANDA filers remain in play challenging patents shielding Esperion’s Nexletol (bempedoic acid) after Micro Labs deal out litigation via a settlement agreement.

Teva’s Uzedy Continues Surge As Olanzapine LAI Filing Nudges Closer

 
• By Dean Rudge

Teva underlined that it was “very pleased with this franchise we’re building and what we’ll bring to the care of patients with schizophrenia,” as it looks ahead to filing its olanzapine new drug application in the second half of 2025.

Cutting Out The Middlemen? Trump’s Pricing Order Offers Opportunity On PBMs

 
• By Dave Wallace

Donald Trump’s executive order on most-favored-nation prescription drug pricing could provide positive opportunities for the off-patent industry, although US generics and biosimilars association the AAM suggested that the administration might do more good by focusing elsewhere.